trending Market Intelligence /marketintelligence/en/news-insights/trending/0UhoRVBe47irelYpzDaIAg2 content esgSubNav
In This List

Argos Therapeutics, Personalis enter research agreement

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Argos Therapeutics, Personalis enter research agreement

Argos Therapeutics Inc. entered a strategic research agreement with Personalis Inc. focused on genomics solutions for immuno-oncology, cancer and genetic disease.

Personalis will serve as the primary genomic analysis service provider to support ongoing research efforts to demonstrate that Argos' lead product candidate, rocapuldencel-T, specifically targets patient-specific neoantigens without having to identify them first.

Argos will utilize the Personalis' ACE ImmunoID sequencing platform to evaluate tumor samples collected during clinical development of its tumor-specific dendritic cell technology to treat renal cell carcinoma.

Rocapuldencel-T is being evaluated in a phase 3 clinical trial for the treatment of metastatic renal cell carcinoma. It is also s being studied in phase 2 investigator-initiated clinical trials as neoadjuvant therapy for renal cell carcinoma and for the treatment of nonsmall cell lung cancer.